Benitec Biopharma Inc. (BNTC) is a publicly traded company in the Unknown sector. Across all available filings, 8 corporate insiders have executed 28 transactions totaling $23.9M, demonstrating a bullish sentiment with $23.9M in net insider flow. The most recent transaction on Jan 22, 2026 involved a transaction of 31,500 shares valued at $0.
No significant insider buying has been recorded for BNTC in the recent period.
No significant insider selling has been recorded for BNTC in the recent period.
Based on recent SEC filings, insider sentiment for BNTC is bullish with an Insider Alignment Score of 100/100 and a net flow of $23.9M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Benitec Biopharma Inc. (BNTC) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 8 insiders are actively trading BNTC stock, having executed 28 transactions in the past 90 days. The most active insider is Master Fund, Ltd. Averill (Executive), who has made 5 transactions totaling $21.1M.
Get notified when executives and directors at BNTC file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 22, 2026 | Mates Sharon | Executive | Award | 31,500 | $N/A | $0 | |
| Dec 29, 2025 | Cowen Aaron | Executive | Purchase | 11,587 | $13.44 | $155.7K | |
| Dec 29, 2025 | Cowen Aaron | Executive | Purchase | 65,800 | $13.44 | $884.4K | Large |
| Dec 26, 2025 | Cowen Aaron | Executive | Purchase | 2,516 | $13.10 | $33.0K | |
| Dec 26, 2025 | Cowen Aaron | Executive | Purchase | 14,320 | $13.10 | $187.6K | |
| Dec 23, 2025 | Cowen Aaron | Executive | Purchase | 42,600 | $12.85 | $547.4K | Large |
| Dec 23, 2025 | Cowen Aaron | Executive | Purchase | 7,400 | $12.85 | $95.1K | |
| Dec 22, 2025 | Master Fund, Ltd. Averill Madison | Executive | Purchase | 2,892 | $12.08 | $34.9K | |
| Dec 22, 2025 | Master Fund, Ltd. Averill Madison | Executive | Purchase | 16,650 | $12.08 | $201.1K | |
| Dec 19, 2025 | Master Fund, Ltd. Averill Madison | Executive | Purchase | 13,950 | $11.48 | $160.1K | |
| Dec 19, 2025 | Master Fund, Ltd. Averill Madison | Executive | Purchase | 2,434 | $11.48 | $27.9K | |
| Dec 18, 2025 | Master Fund, Ltd. Averill Madison | Executive | Purchase | 1,515 | $11.24 | $17.0K | |
| Dec 18, 2025 | Master Fund, Ltd. Averill Madison | Executive | Purchase | 8,700 | $11.24 | $97.8K | |
| Nov 7, 2025 | Management, Llc Suvretta Capital | Executive | Purchase | 730,370 | $13.50 | $9.9M | Large |
| Nov 7, 2025 | Management, Llc Suvretta Capital | Executive | Purchase | 751,111 | $13.50 | $10.1M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 22 | $23.9M | 53.1% |
Exercise (Options)(X) | 5 | $21.1M | 46.9% |
Award(A) | 1 | $0 | 0.0% |
Insiders at Benitec Biopharma Inc. are accumulating shares at an accelerated pace. With 8 insiders making 28 transactions totaling $23.9M in purchases versus $0 in sales, the net buying activity of $23.9M signals strong executive confidence. Master Fund, Ltd. Averill (Executive) leads the buying activity with $21.1M in transactions across all time.